mProX™ Human CXCR5 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- GPCR Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human CXCR5 Stable Cell Line (S01YF-0923-PY48). Click the button above to contact us or submit your feedback about this product.
Charles (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Elizabeth (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 CXCL13/CXCR5 axis promoted ccRCC cells proliferation.
Suppression of CXCR5 gene expression hampered CXCL13-induced cell growth in ccRCC cells, as confirmed through the cell proliferation assay (evaluated using Student's t-test, *P < 0.05).
Ref: Zheng, Zaosong, et al. "CXCL13/CXCR5 axis predicts poor prognosis and promotes progression through PI3K/AKT/mTOR pathway in clear cell renal cell carcinoma." Frontiers in oncology 8 (2019): 682.
Pubmed: 30723697
DOI: 10.3389/fonc.2018.00682
Research Highlights
Zacharias ZR, Houtman JCD. "OMIP-099: 31-color spectral flow cytometry panel to investigate the steady-state ." Cytometry. Part A : the journal of the International Society for Analytical , 2023.
The authors have developed a novel 31-color panel to define the steady-state phenotype of T cells in human peripheral blood (Table 1). The panel was optimized using cryopreserved peripheral blood mononuclear cells (PBMC) and includes markers such as CD45RA, CD45RO, CCR7, and CD95, which were carefully selected to characterize the main subsets (e.g., naive, T(EM), T(CM), T(EMRA), T(SCM), etc.) of CD4, CD8, and gammadelta T cells. Additionally, the panel includes markers to identify differentiation status (CD27, CD28), activation/antigen experience status (CD11a, CD49d, CD38, HLA-DR, CD56, CD39), co-inhibitory marker expression (PD-1, TIM-3), and CD4 T helper subsets (CXCR3, CXCR5, CCR4, CCR6, Foxp3, CD25, CD127). This optimized panel offers a comprehensive evaluation of the steady-state phenotype of human T cells.
Pubmed:
37814476
DOI:
10.1002/cyto.a.24799
Tang HY, et al. "[Identification and preliminary validation of potential biomarkers in the ." Zhonghua yi xue za zhi, 2023.
The study aimed to compare the peripheral blood mononuclear cell (PBMC) transcripts of patients with atopic dermatitis (AD) and healthy individuals, and to identify and validate potential biomarkers of AD. Samples were collected from 9 AD patients and 10 healthy controls between January 2021 and May 2022 at the Dermatology and Cosmetic Center of the Third Affiliated Hospital of Chongqing Medical University. RNA-sequencing (RNA-seq) was used to analyze PBMC transcriptome and differential gene expression. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interaction (PPI) network analysis were conducted to identify differentially expressed genes (DEGs). Quantitative real-time PCR (qRT-PCR) was used to validate potential biomarkers. Results showed that the AD group had 1,044 DEGs, including 668 up-regulated and 376 down-regulated genes, compared to healthy controls. Additionally, differential variable splicing (AS) analysis revealed a high proportion of mutually exclusive exons (46.74%) and skipped exons (31.01%) in AD patients. GO and KEGG enrichment analysis suggested that AD is associated with DEGs involved in the inflammatory response, cytokine interaction, and signaling pathways. PPI analysis and comprehensive enrichment analysis identified 8 candidate genes (CCL4, CCR3, CXCR5, NFKBIA, CXCL1, IL-1B, CCL20, LY96), which were verified by qRT-PCR and consistent with RNA-seq results. In conclusion, potential biomarkers for AD (CCL4, CCR3, CXCR5, NFKBIA, CXCL1, IL-1B, CCL20, LY96) were identified, suggesting their involvement in the pathogenesis of AD.
Pubmed:
37813654
DOI:
10.3760/cma.j.cn112137-20230128-00128